

By Senator Garcia

36-00967-26

2026596__

A bill to be entitled
An act relating to transparency in health care;
creating s. 456.0525, F.S.; defining the term
"personal benefit"; requiring health care
practitioners to report any personal benefit received
from a pharmaceutical company to the Department of
Health; requiring that such reports be updated at
least quarterly and include certain information;
requiring the department to establish uniform
reporting procedures and a publicly accessible online
database for the reports; providing requirements for
the database; requiring the department to establish
certain guidelines for health care practitioners;
requiring the Auditor General to perform annual audits
for specified purposes; providing for administrative
and criminal penalties; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. Section 456.0525, Florida Statutes, is created
to read:

456.0525 Disclosure of personal benefits received from
pharmaceutical companies.—

(1) As used in this section, the term "personal benefit"
means any benefit or advantage, economic or noneconomic,
received outside of the context of a health care practitioner-
patient relationship. The term includes, but is not limited to,
investment interests, gifts, financial incentives, kickback
fees, speaking fees, sponsored travel, research funding, free

36-00967-26

2026596__

30 samples, and any other form of compensation.

31 (2) To promote transparency, accountability, and public
32 trust in health care in this state, each health care
33 practitioner shall report to the department any personal benefit
34 received from a pharmaceutical company. Reports must be updated
35 at least quarterly and include, at a minimum, details regarding
36 the nature, value, and purpose of any personal benefit received.

37 (3) The department shall establish uniform reporting
38 procedures and a publicly accessible online database to maintain
39 the reports. The database must allow members of the public to
40 easily search by the name of a health care practitioner or
41 pharmaceutical company and the type of personal benefit
42 received.

43 (4) The department shall establish guidelines for health
44 care practitioners relating to ethical practices when engaging
45 with pharmaceutical companies.

46 (5) The Auditor General shall perform annual audits to
47 monitor compliance with this section, verify the accuracy of
48 reported data, and address any conflicts of interest.

49 (6) A violation of this section is grounds for disciplinary
50 action by the applicable board. A second or subsequent violation
51 of this section constitutes a misdemeanor of the first degree,
52 punishable as provided in s. 775.082 or s. 775.083.

53 Section 2. This act shall take effect July 1, 2026.